Payment overview · 2025
General Payments
$378.02
19 reported records · 10 companies
Healthcare provider profile · identity verified
Robert F Deuell, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, TX · NPI 1407894959
Verified facts
What the public records show
CMS Open Payments records show Robert F Deuell, MD received $378.02 in general payments during 2025 across 19 reported records.
Corcept Therapeutics accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $88.20 | 23.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.52 | 22.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.02 | 11.1% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.01 | 10.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.46 | 7.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.58 | 6.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.80 | 5.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.46 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.31 | 4.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.66 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.02 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $88.20 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.99 | 3 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $39.01 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 104 |
| Alprazolam | Alprazolam | 233 | 53 |
| Lisinopril | Lisinopril | 222 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 214 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 65 |
| Gabapentin | Gabapentin | 169 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 29 |
| Omeprazole | Omeprazole | 161 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 59 |
| Metformin Hcl | Metformin Hcl | 155 | 48 |
| Losartan Potassium | Losartan Potassium | 151 | 47 |
| Simvastatin | Simvastatin | 149 | 55 |
| Montelukast Sodium | Montelukast Sodium | 96 | 36 |
| Furosemide | Furosemide | 92 | 42 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 33 |
| Sertraline Hcl | Sertraline Hcl | 80 | 22 |
| Clonazepam | Clonazepam | 79 | 13 |
| Meloxicam | Meloxicam | 74 | 24 |
| Allopurinol | Allopurinol | 73 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 22 |
| Celecoxib | Celecoxib | 67 | 18 |
| Potassium Chloride | Potassium Chloride | 67 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 28 |
| Terazosin Hcl | Terazosin Hcl | 66 | 17 |
| Glimepiride | Glimepiride | 63 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 15 |
| Trazodone Hcl | Trazodone Hcl | 57 | 21 |
| Temazepam | Temazepam | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 18 |
| Fenofibrate | Fenofibrate | 53 | 16 |
| Glipizide Er | Glipizide | 52 | 16 |
| Tramadol Hcl | Tramadol Hcl | 52 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 19 |
| Donepezil Hcl | Donepezil Hcl | 49 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 20 |
| Pregabalin | Pregabalin | 48 | 15 |
| Carvedilol | Carvedilol | 46 | 15 |
| Alendronate Sodium | Alendronate Sodium | 45 | 20 |
| Bupropion Xl | Bupropion Hcl | 45 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 38 |
| Ozempic | Semaglutide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 14 |
| Memantine Hcl | Memantine Hcl | 36 | 11 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Eliquis | Apixaban | 34 | 13 |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 28 |
| Finasteride | Finasteride | 30 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Cefdinir | Cefdinir | 12 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.02 · 19 records | Corcept Therapeutics | AIRSUPRA, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, GOMEKLI, KRYSTEXXA, Korlym, NURTEC ODT, REXULTI, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error